Radnostix, Inc. filings document the public-company record of the radioisotope manufacturer formerly known as International Isotopes Inc. Recent 8-K and information-statement disclosures record the amendment to its Texas formation documents changing the corporate name, shareholder written-consent approval, and the continued OTCQB trading of its common stock under INIS.
Other filings and event reports cover executive-compensation arrangements, material agreements, shareholder voting matters, capital-structure disclosure, operating and financial results, and regulatory matters connected with radioisotope, theranostics, medical-device, calibration and reference products.
Radnostix Inc. filed a Notification of Late Filing (Form 12b-25) stating it could not timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 because additional time is needed to complete valuation and accounting analyses of certain stock-based compensation awards, including restricted stock units. The company expects to file the Form 10-Q within the five-day extension period.
The filing discloses operating results for the three months ended March 31, 2026: Sales $2,378,924 versus $3,238,900 for the same period in 2025 (a decrease of approximately 27%). Radnostix expects a net loss of $1,100,000 to $1,300,000 for the quarter, versus a net loss of $112,694 in the prior-year period, attributing the change mainly to decreased sales after voluntary recalls and an operational shutdown for rehabilitation.
Radnostix, Inc. disclosure: Kennerman Associates, Inc. reports beneficial ownership of 237,489,559 shares of common stock, representing 42.4% of the class based on March 26, 2026. The holding includes 5,000,000 vested options exercisable within 60 days and 26,300,000 shares issuable on conversion of Series C Preferred Stock.
Christopher Grosso is identified as a principal of Kennerman Associates and is reported as beneficially owning 65,645,540 shares (12.1%), which includes options and Series C conversion rights; Grosso disclaims beneficial ownership of a portion of the securities reported.
RADNOSTIX INC director and 10% owner Christopher G. Grosso reported non-market restructuring transactions involving 581,536 shares of Common Stock. These entries reflect shares issued in lieu of cash dividends on the company’s Series C Redeemable Convertible Preferred Stock, at the holder’s option, rather than open-market buying or selling.
The shares were allocated across several indirect accounts, including a credit shelter trust and UTMA custodial accounts for his children, as well as his direct holdings. After these stock-dividend issuances, his reported direct Common Stock position was 38,477,083 shares, with additional indirect holdings in the related accounts.
Radnostix Inc. files an amended annual report to add detailed disclosures on directors, executive compensation, share ownership, related‑party dealings and auditor fees for the year ended December 31, 2025.
The filing highlights a five‑member board with Nasdaq‑independent committees, a performance‑ and stock‑based package for the CEO, concentration of ownership among two large shareholders, insider promissory notes that can convert into equity, and audit fees of about $122,000 per year paid to Haynie & Company.
Radnostix Inc. reported 2025 revenue of $13.1 million, down about 6% from 2024, and swung to a net loss of $908,002 after a small profit in the prior year. Gross margin remained relatively strong at 59% but was slightly lower than 62% in 2024.
Theranostics Products stayed the largest segment at $6.8 million, though sales fell 15% due to radioisotope supply outages and softer demand from a major customer. Cobalt Products revenue declined 26% to $1.8 million, partly because the company shut cobalt production hot cells in late 2025 for refurbishment.
Calibration & Reference Products grew 21% to $4.25 million, helped by a full year of cobalt‑57 supply and new PET-focused products, offset by a gadolinium‑153 isotope outage. The Medical Devices segment remained small but rose sharply to $229,000 as initial distribution activity ramped up.
Operating expenses were flat at about $8.7 million, with higher salaries offset by lower legal, professional, and R&D spending. Radnostix generated $620,000 of operating cash flow and ended 2025 with $1.7 million in cash. The company also terminated a planned $12.45 million sale of its DUF6 de‑conversion assets, retaining those assets and related NRC licenses for future strategic options.
Radnostix, Inc. terminated its Asset Purchase Agreement with American Fuel Resources for the sale of its depleted uranium deconversion and fluorine extraction plant. The decision followed AFR’s request for a one-year extension after it could not pay the remaining $12,450,000 purchase price by the March 31, 2026 outside date.
AFR had previously made a non‑refundable $50,000 prepayment and twelve non‑refundable NRC extension fee payments totaling $120,000. With termination, Radnostix retains ownership of the DUF6 plant, which it believes has appreciated in value, and plans to evaluate future options for these assets.
The company also initiated a voluntary recall of specific lots of its Dibasic Sodium Phosphate Capsules shipped between August 19, 2024 and February 17, 2026. It expects a one‑time charge of about $75,000 in fourth‑quarter 2025 for inventory write‑offs and about $50,000 in first‑quarter 2026 for customer refunds, plus roughly $75,000 for new capsule inventory and an estimated $25,000 to $75,000 per week in lost revenue, which it believes will not extend beyond the second quarter.
International Isotopes Inc. reported that it has changed its corporate name to Radnostix, Inc. by filing a Certificate of Amendment in Texas on December 23, 2025. The board approved the change on October 21, 2025, and a majority of shareholders approved it by written consent on November 25, 2025.
The company explains that its business has expanded from radiochemicals and non-medical radioisotopes with an energy focus to a broader portfolio of radioisotope, theranostic, and related healthcare products and devices. Management believes the Radnostix, Inc. name better reflects this healthcare-focused direction. The common stock will continue to trade under the ticker "INIS" on the OTCQB, and shareholders do not need to take any action regarding existing stock certificates.
International Isotopes Inc. (INIS) has obtained written consent from shareholders holding approximately 52.1% of its common stock to amend its Certificate of Formation and change its corporate name to Radnostix, Inc. The board of directors unanimously approved the name change on October 21, 2025, and shareholders of record on November 24, 2025, representing 275,232,379 votes out of 528,209,538 outstanding shares, approved it by written consent in lieu of a meeting.
The change reflects a business shift from primarily energy‑sector isotopes toward a broader portfolio of radioisotope, theranostics, and related healthcare products, devices, and accessories. No shareholder meeting or proxy is being solicited. The name change will become effective after the company files a certificate of amendment with the Texas Secretary of State, at least 20 days after this Information Statement is first mailed.
International Isotopes Inc. (INIS) reported Q3 2025 results with sale of product of $3,277,816 and a net loss of $203,601. For the nine months ended September 30, 2025, sale of product was $10,172,036 and net loss was $477,080. Gross margin held near 59% in Q3 as operating expenses declined 7% year over year.
The company advanced its planned divestiture of the Fluorine Products and de‑conversion assets, noting total cash consideration of $12.5 million if the deal closes by the Outside Date of March 31, 2026. On September 30, 2025, INIS and the buyer submitted an application to the NRC to transfer the license; closing remains subject to financing and regulatory approvals.
Theranostics revenue fell on a temporary supplier outage and partial account loss, while Calibration & Reference grew; management cites an additional approved supplier from September. Cash and cash equivalents were $1,651,548 with restricted cash of $1,477,685. INIS disclosed an FDA inspection in April resulting in an OAI; corrective actions have been submitted and manufacturing continues pending reinspection.
International Isotopes Inc. (INIS) approved a new employment agreement for CEO and President Shahe Bagerdjian. The term runs from July 18, 2025 to July 18, 2030, with an initial base salary of $314,000 and automatic 5% annual increases. He may receive additional $50,000 salary increases as quarterly revenue reaches $3.75M, $6.25M, $12.5M, $18.75M, and $25M, excluding one-time other income items.
The agreement grants 37,500,000 RSUs, vesting after the share price is at or above $0.10 (2.5M), $0.15 (5.0M), $0.20 (7.5M), $0.25 (10.0M), and $0.30 (12.5M) for 60 consecutive days and subject to a tax‑withholding cash condition or six months after the trigger date. Unvested RSUs accelerate upon termination without cause or immediately before a change of control while in good standing. He remains eligible for annual cash bonuses set by the Board.
Governance updates: Dr. Duke W. Fu was appointed an independent director and to the audit committee; he will receive 250,000 RSUs per annual term (vesting commencement July 11, 2026). The Board amended bylaws to limit special-meeting business to noticed items, add advance notice for business and director nominations, permit advisory directors, allow shareholder action by less than unanimous written consent, and add indemnification and insurance provisions.